Tag: Mindset Pharma - Page 4 - Psychedelic Alpha

Read more about the article Mindset Pharma Develops Highly Specialized Preclinical Rodent Trained Studies with Its Drugs to Differentiate Between Their Psychedelic and Non-Psychedelic Effects

Mindset Pharma Develops Highly Specialized Preclinical Rodent Trained Studies with Its Drugs to Differentiate Between Their Psychedelic and Non-Psychedelic Effects

Post published:September 7, 2021
Post category:Press Release

Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic Analogs Demonstrate a Significantly Improved Safety Profile in Preclinical Results

Post published:August 31, 2021
Post category:Press Release

Read more about the article Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in its Long-Acting Next Generation Psychedelic Compounds

Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in its Long-Acting Next Generation Psychedelic Compounds

Post published:August 26, 2021
Post category:Press Release

Read more about the article Mindset Pharma Broadens its IP Portfolio by Filing U.S. Provisional Patent Extending its DMT and 5-MeO-DMT Inspired Psychedelic Drug Candidates

Mindset Pharma Broadens its IP Portfolio by Filing U.S. Provisional Patent Extending its DMT and 5-MeO-DMT Inspired Psychedelic Drug Candidates

Post published:August 24, 2021
Post category:Press Release

Read more about the article Mindset Pharma Announces Publication of Three PCT Patent Applications for Its Next Generation Psychedelic Drug Candidates

Mindset Pharma Announces Publication of Three PCT Patent Applications for Its Next Generation Psychedelic Drug Candidates

Post published:August 16, 2021
Post category:Press Release

Read more about the article Mindset Pharma Announces Appointment of Clinician Scientist, Dr. Ishrat Husain, to Scientific Advisory Board

Mindset Pharma Announces Appointment of Clinician Scientist, Dr. Ishrat Husain, to Scientific Advisory Board

Post published:July 20, 2021
Post category:Press Release

Read more about the article Mindset Pharma Announces Additional Preclinical Results Suggesting Superior Efficacy and Improved Safety in Head-to-Head Comparison to Psilocybin for its First Lead Clinical Candidate, MSP-1014

Mindset Pharma Announces Additional Preclinical Results Suggesting Superior Efficacy and Improved Safety in Head-to-Head Comparison to Psilocybin for its First Lead Clinical Candidate, MSP-1014

Post published:July 7, 2021
Post category:Press Release

Read more about the article Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine

Post published:June 3, 2021
Post category:Press Release

Read more about the article Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds

Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds

Post published:April 29, 2021
Post category:Press Release

Read more about the article Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform (“Cope”); Cope Expected to Be World’s First in Vivo Psychedelic Benchmark Data Set

Mindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform (“Cope”); Cope Expected to Be World’s First in Vivo Psychedelic Benchmark Data Set

Post published:March 23, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.